Table 2.
Electrophysiological and procedural characteristics of the study population
| HD Grid n = 33 |
Pentaray n = 22 |
Duodeca n = 12 |
RF n = 6 |
p value | ||
|---|---|---|---|---|---|---|
| GA, n (%) | 6 (18) | 6 (27) | 2 (17) | 1 (17) | 0.83 | |
| RV mapping, n (%) | 7 (21) | 3 (14) | 3 (25) | 1 (17) | 0.71 | |
| LV mapping, n (%) | 31 (94) | 22 (100) | 12 (100) | 5 (83) | 0.24 | |
| Endocardial mapping, n (%) | 33 (100) | 21 (95) | 12 (100) | 6 (100) | 0.50 | |
| Epicardial mapping, n (%) | 7 (21) | 1 (4) | 2 (16) | 0 | 0.24 | |
| Epicardial access, n (%) | 7 (21) | 1 (4) | 1 (8) | 0 | 0.20 | |
| Pre-ablation PES, n (%) | 9 (27) | 5 (23) | 6 (50) | 5 (83) | 0.02 | |
| VT hemodynamically stable, n (%) | 18 (55) | 12 (55) | 8 (67) | 3 (50) | 0.88 | |
| VT CL ms, mean ± SD | 364 ± 68 | 382 ± 86 | 371 ± 54 | 358 ± 65 | 0.91 | |
| Substrate map, n (%) | 33 (100) | 22 (100) | 11 (92) | 5 (83) | 0.06 | |
| Activation map, n (%) | 27 (82) | 14 (64) | 11 (92) | 2 (33) | 0.025 | |
| Pace map, n (%) | 20 (61) | 11 (50) | 11 (92) | 4 (67) | 0.11 | |
| Pace map >11/12, n (%) | 19 (58) | 10 (45) | 10 (83) | 1 (17) | 0.039 | |
| Entrainment map, n (%) | 7 (21) | 5 (23) | 4 (33) | 0 | 0.45 | |
| RF catheter | Smart Touch, n (%) | 0 | 22 (100) | 0 | 4 (66) | < 0.001 |
| Tacticath, n (%) | 33 (100) | 0 | 12 (100) | 2 (33) | < 0.001 | |
| VTs induced/case, mean ± SD | 2.1 ± 0.4 | 1.9 ± 1.1 | 1.8 ± 0.5 | 1.3 ± 0.8 | 0.11 | |
| VTs mapped, mean ± SD | 1.5 ± 0.7 | 1.7 ± 1.46 | 1.25 ± 0.45 | 0.5 ± 0.5 | 0.06 | |
| VTs ablated, mean ± SD | 1.4 ± 0.7 | 1.6 ± 1.46 | 1.25 ± 0.45 | 0.5 ± 0.5 | 0.09 | |
| Initial substrate map time (min), mean ± SD | 37 ± 10.9 | 63 ± 20.2 | 55 ± 16 | 96 ± 23.6 | < 0.001 | |
| Number of maps/case, mean ± SD | 2.3 ± 0.68 | 1.3 ± 0.46 | 1.5 ± 0.52 | 1 ± 0 | < 0.001 | |
| Mapping points/map, mean ± SD | 2687 ± 2192 | 1426 ± 1192 | 1256 ± 892 | 207 ± 202 | < 0.001 | |
| Post-procedure clinical VT inducible, n (%) | 1 (3) | 4 (18) | 2 (17) | 3 (50) | 0.016 | |
| Post-procedure non-clinical VT inducible, n (%) | 7 (21) | 9 (41) | 1 (8) | 4 (67) | 0.027 | |
| Elimination of all clinical & non-clinical VTs n,(%) | 26 (79) | 12 (55) | 10 (83) | 2 (33) | 0.04 | |
| Complications, n (%) | 2 (6) | 2 (9) | 1 (8) | 1 (17) | 0.68 | |
| RF total (min), mean ± SD | 42 ± 19 | 62 ± 18 | 34 ± 18 | 29 ± 10 | 0.001 | |
| Fluoroscopy time (min), mean ± SD | 34.5 ± 14 | 28.5 ± 8.3 | 31.9 ± 6.3 | 30.3 ± 11.3 | 0.31 | |
| Procedure time (min), mean ± SD | 350 ± 105 | 261 ± 59 | 257 ± 74 | 239 ± 72 | < 0.001 | |
| Post procedure echo, n (%) | 33 (100) | 21 (95) | 12 (100) | 6 (100) | 0.50 |
GA general anesthesia, PES pulsed electrical stimulation, CL cycle length